Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial

Overview of attention for article published in The Lancet, August 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 5 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 28 X users

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
f1000: 1 research highlight platform

Citations

dimensions_citation: 102 Dimensions

Readers on

mendeley: 129 Mendeley

Summary News Blogs Policy documents X Facebook Wikipedia Research highlights Dimensions citations

So far, Altmetric has seen 37 X posts from 28 X users, with an upper bound of 107,149 followers.

@ABsteward With clinical effectiveness demonstrated in a trial led by @AshaBowen here: https://t.co/zi58p4sITf

16 Dec 2023

Reply Repost Favourite

Millionth reason why I love #IDtwitter. Discovering clinical studies that destroy myths 👇

14 Jun 2023

Reply Repost Favourite

@dralicehan @OncIDPharmd @PaulSaxMD @AntibioticDoc @DrToddLee @GermHunterMD Do you mean clinical study of iGAS? If SSTI, TMP/SMZ equivalent B-lactam to in microbiologically proven GAS impetigo: https://t.co/sWdUfkXDVx With no B-lactam resistance, there

14 Jun 2023

Reply Repost Favourite

@Cortes_Penfield Was the Skin Sore Trial mentioned? TMP/SMZ for GAS related impetigo in Aboriginal children. Non inferior to IM benzathine penicillin https://t.co/IwhLwa2yZR

21 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 33 additional X posts.